COSCIENS Biopharma Inc.

CSCIF OTC SEC CIK 1113423
Follow COSCIENS Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
Revenue, last quarter $1.8M −46.8% vs same quarter last year
Net income −$2.2M +67.6% vs same quarter last year
EPS, diluted -
Operating cash flow −$1.5M +51% vs same quarter last year
Revenue by quarter
$2.1M
$2.3M
$1.9M
$3.3M
$1.5M
$2.7M
$1.5M
$1.8M
Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20M$40MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$7.5M−$10.4M
FY24$9.6M−$15.3M
FY23$7.1M−$3.5M
FY22$14.6M$3.4M
FY21$5.3M−$8.4M
FY20$3.7M−$5.1M
FY19$532K−$6M
FY18$26.9M$4.2M
FY17$923K−$16.8M
FY16$911K−$25M
FY15$545K−$50.1M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−10000%−7500%−5000%−2500%0%2500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2535.3%−142.5%−138.1%
FY2449.3%−190.7%−159.7%
FY2341.1%−64.8%−48.8%
FY2258.7%29.6%23.7%
FY2198.3%−164.8%−159.1%
FY2036.6%−156.2%−140.1%
FY1922.9%−1925.2%−1135.7%
FY1892.2%36.6%15.6%
FY17100%−2499.9%−1819.7%
FY16100%−3235.6%−2739.7%
FY15-−6400.7%−9200.6%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$40M−$20M$0$20MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$9.2M
FY24−$15.7M
FY23−$3.3M
FY22$4.9M
FY21−$8.6M
FY20-
FY19-
FY18$6.8M
FY17−$22.9M
FY16−$29.1M
FY15−$33.9M
FY14-
Net margin vs the sectorMedian of Materials companies filing with the SEC
  • COSCIENS Biopharma
  • Materials median
−10000%−7500%−5000%−2500%0%2500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearCOSCIENS BiopharmaMaterials median
FY25−138.1%2.3%
FY24−159.7%3.4%
FY23−48.8%4.4%
FY2223.7%5.6%
FY21−159.1%6.4%
FY20−140.1%4.1%
FY19−1135.7%4.1%
FY1815.6%5%
FY17−1819.7%4.9%
FY16−2739.7%4.8%
FY15−9200.6%3.3%
FY14-4.5%